These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39024528)

  • 1. Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.
    Sra MS; Sasi A; Batra A; Bakhshi S; Ganguly S
    JCO Glob Oncol; 2024 Jul; 10():e2300433. PubMed ID: 39024528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.
    Chang SH; Svensson M; Hsin-Min Wang G; Wang Y; Kang HR; Park H
    J Manag Care Spec Pharm; 2024 Sep; 30(9):942-953. PubMed ID: 39213142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Zhang B; Long EF
    Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.
    Wan X; Zhang Y; Ma J; Tan C; Zeng X; Peng L
    Breast; 2019 Feb; 43():1-6. PubMed ID: 30342258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
    Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
    Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
    Huang X; Lin S; Rao X; Zeng D; Wang H; Weng X; Huang P
    Clin Breast Cancer; 2021 Aug; 21(4):e479-e488. PubMed ID: 33676870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer.
    Jiang W; He Z; Zhang T; Guo C; Zhao J; Zhu J; Wu J; Yu X; Chen C; Li J; Jiang J
    Immunotherapy; 2021 Jun; 13(8):661-668. PubMed ID: 33876668
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2- breast cancer in Mexico.
    Molina-Jaimes M; Galindo-González A; Verduzco-Aguirre HC; Bautista-Arredondo S; Reyes-Terán G; Soto-Perez-de-Celis E
    Clin Transl Oncol; 2024 Jan; 26(1):239-244. PubMed ID: 37329428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
    Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.
    Loke L; Lee SC; Pearce F; Ng K; Aziz MIA
    Cancer Rep (Hoboken); 2021 Feb; 4(1):e1308. PubMed ID: 33085843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs.
    Giuliani J; Bonetti A
    Clin Breast Cancer; 2019 Aug; 19(4):e519-e521. PubMed ID: 30858036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: a systematic review and meta-analysis.
    Masurkar PP; Prajapati P; Canedo J; Goswami S; Earl S; Bhattacharya K
    Curr Med Res Opin; 2024 Oct; 40(10):1753-1767. PubMed ID: 39305463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.
    Giuliani J; Bonetti A
    J Oncol Pharm Pract; 2020 Sep; 26(6):1486-1491. PubMed ID: 32576084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Chandiwana D; Park J; Delea TE
    Pharmacoeconomics; 2021 Jul; 39(7):853-867. PubMed ID: 34002341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.